Columbian scientists tap global computer network in search of leishmaniasis drugs

"Colombian scientists are using a global network of personal and institutional computers to search for potential drugs against leishmaniasis, a disease that affects 12 million people worldwide," SciDev.Net reports. The researchers at the University of Antioquia "will harness the calculation potential of the almost two million computers that make up the World Community Grid, funded by the IBM Corporation," the news service writes.

"Carlos Muskus, the project leader, ... told SciDev.Net that, thanks to the grid, 100 years-worth of work can now be carried out in less than three years," SciDev.Net notes, adding, "The project will use an existing open-access database of 13 million drugs to find those that can destroy or inactivate some of the leishmaniasis parasite's 53 proteins." According to the news service, "Muskus said that promising drug candidates would undergo a series of tests before clinical trials and eventual release as a treatment" (Correa, 9/30).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
A new era of targeted therapy with antibody–drug conjugates